Lecia V. Sequist, MD | Authors

January 23, 2015

Lecia V. Sequist, MD, discusses the unanswered question of which EGFR TKI to use in the frontline setting of NSCLC.

July 30, 2014

Lecia V. Sequist, MD, medical oncologist, associate professor, Massachusetts General Hospital, Harvard Medical School, discusses adverse events (AEs) associated with CO-1686 for patients with non-small cell lung cancer (NSCLC).